Reinforces Leadership at Dxcover with Elite Scientific Advisers and Board Members of Global Repute
Dxcover, a pioneering company in the field of diagnostics, has made significant strides in bolstering its leadership team with the appointment of two new Non-Executive Directors. These appointments are aimed at supporting the company's US expansion and revenue-stage growth.
The company has expanded its Scientific Advisory Board (SAB) and Board of Directors by adding seasoned professionals with expertise in neurology, gynecological and pancreatic oncology, clinical statistics, artificial intelligence, and commercial diagnostics.
Reinforcement of the Scientific Advisory Board
The new members joining the SAB include Professor Katy Peters, a Professor of Neurology and Neurosurgery at Duke University Medical Center, who brings deep knowledge of brain cancer care pathways and translational diagnostic research. Professor Emma Crosbie, Professor of Gynecological Oncology at The University of Manchester and NIHR Research Professor, is another addition to the SAB. She is renowned for her work in early detection and prevention of endometrial and ovarian cancers.
Professor Paul Brennan, a renowned neurosurgeon from the University of Edinburgh with a focus on brain tumors and clinical trials, is already a member of Dxcover's SAB. Dr. Luke Pike, a specialist in CNS malignancies, and Professor William E. Fisher, an expert in pancreatic surgery and oncology, have also been added to the SAB.
Board of Directors' New Member
Professor David Onions, an investor director representing Norcliffe Capital Limited with extensive experience in growing and commercializing life sciences and biotech businesses, has joined the Board of Directors.
Key Figures on the Board
Dr. Holly Butler, the Chief Technical Officer, and Dr. Stephen Little, a diagnostics leader and former CEO of DxS with extensive experience in R&D and diagnostics commercialization, are other key figures on the board.
Together, these appointments strengthen Dxcover’s leadership with top-tier clinical and commercial expertise essential for advancing their Multiomic Spectral Analysis platform (MOSA-Dx™) through clinical translation and commercial growth.
Professor Matthew J. Baker, CEO and inventor of Dxcover, has announced the addition of this distinguished group of scientific and commercial leaders to Dxcover. The appointments are a testament to Dxcover's commitment to revolutionizing diagnostics and making strides in the fight against various cancers.
Background Information
Marc Jones, a seasoned health technology executive with over 25 years' experience, leads the development of digital biomarkers for neurological diseases at Altoida. Stacy Chick, an experienced global commercial life sciences executive, has successfully transitioned diagnostic innovations from research to commercial stage. Chick has advised Dxcover since 2021 and her strategic insights into global market access, reimbursement, and commercial scaling will guide Dxcover in its future endeavours.
[1] Dxcover Press Release, [Link to the press release if available] [2] Duke University Medical Center, [Link to the professor's profile if available] [3] The University of Manchester, [Link to the professor's profile if available] [4] University of Edinburgh, [Link to the professor's profile if available] [5] Norcliffe Capital Limited, [Link to the profile if available] [6] Altoida, [Link to the company's website if available] [7] Sanofi, [Link to the company's website if available] [8] DxS, [Link to the company's website if available]
- Dxcover's US expansion and revenue-stage growth are being supported through the appointment of new Non-Executive Directors, reinforcing their Scientific Advisory Board (SAB) and Board of Directors.
- The SAB appointments include Professor Katy Peters, renowned for her expertise in brain cancer care pathways and translational diagnostic research, and Professor Emma Crosbie, known for endometrial and ovarian cancer early detection and prevention.
- The Board of Directors has a new member, Professor David Onions, an investor director with experience in growing and commercializing life sciences and biotech businesses.
- Dr. Holly Butler, the Chief Technical Officer, and Dr. Stephen Little, a diagnostics leader with extensive experience in R&D and commercialization, are key figures on the board.
- The company seeks to advance their Multiomic Spectral Analysis platform (MOSA-Dx™) through clinical translation and commercial growth with this strengthened leadership team, which includes experts in artificial intelligence, neurology, gynecological and pancreatic oncology, and commercial diagnostics.
- Investments in Dxcover are indicative of its commitment to revolutionizing diagnostics, being active in digital health, health tech, and the broader technology sector, with potential for impact on health-and-wellness, finance, and business via cancer diagnosis and prevention.
